Solana dominated the DEX spot trading in Q1 2026, capturing a 30.6% market share.
BlockBeats News, April 28th, according to CoinGecko data, despite a 26.5% decrease in trading volume, Solana still held the top spot in spot trading with a 30.6% quarterly market share. However, Ethereum surpassed Solana in March with a 27% share (compared to Solana's 26%). BSC held the second position with a slight lead over Ethereum with a 24.5% quarterly market share (compared to Ethereum's 23.7%), but its trading volume decline was more significant, and it is expected to fall to third place in the second quarter.
In addition, Monad, which launched its mainnet in November 2025 during the early stages of the bear market, has seen a gradual increase in trading volume. It has now risen to become the tenth most active chain in spot trading, surpassing Unichain and Optimism.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
A key leap toward the internationalization of the Korean won: The Bank of Korea launches a trial run of its 24/7 international settlement system, with full deployment set for January next year.
The Bank of Korea officially launched the trial operation of the "BOK Won International Payment Network" on Monday local time.
Offshore oil and gas module equipment company VME (VME.US) aiming for Nasdaq listing, plans to raise up to 30 million USD
Offshore oil and gas process module and separation equipment company VME Companies has applied for an IPO on Nasdaq, aiming to raise up to $30 million, with Kingswood as the sole bookrunner.
Hypertension drug developer Retension (RTSN.US) applies for US listing, plans to raise $58 million.
U.S. hypertension drug developer Retension Pharmaceuticals filed documents with the SEC last Friday, planning to raise up to $58 million through an initial public offering (IPO).
Pfizer (PFE.US) overseas price increase gains to be shared with the U.S. government: "Most Favored Nation" contract revealed, over twenty transactions still confidential
According to reports, under a new contract with the U.S. Department of Health and Human Services, Pfizer will share higher overseas drug revenues with the United States.
